Abbott Laboratories Reports Strong Q1 2025 Performance

Abbott Laboratories has announced a robust start to 2025, with first-quarter revenue climbing 4% year-over-year to $10.4 billion. The company's net earnings saw an impressive 8.2% increase, reaching $1.3 billion, while diluted earnings per share (EPS) rose by 8.6% to $0.76.

Leadership Comments on Diversified Business Model

"Abbott's diversified business model continues to be a cornerstone of our success, enabling top-tier sales and EPS growth even in uncertain times," stated CEO Robert Ford. He emphasized the company's ability to deliver sustainable growth through strategic execution and diversification.

Reaffirmed 2025 Guidance

The company remains confident in its 2025 outlook, projecting organic sales growth between 7.5% to 8.5%. Additionally, Abbott anticipates an adjusted operating margin of 23.5% to 24.0% of sales and adjusted diluted EPS ranging from $5.05 to $5.25.